Yakup Ergün· @dr_yakupergun · X·· 2 天前评分70
正文 · 原文
#ESMO26 | FINER
In HR+/HER2− mBC, ipatasertib + fulvestrant failed to demonstrate an OS benefit despite improving PFS (26.7 vs 25.8 mo; HR 1.14).
No OS benefit was observed in patients with AKT pathway alterations either (HR 1.14)!!!
I’m eagerly awaiting the presentation details to better understand why the PFS benefit did not translate into an OS advantage.
316 浏览 · 1 赞 · 2 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：Yakup Ergün · x.com